Atossa Therapeutics, Inc.’s Post

Dosing the first patient in this trial marks a significant milestone for Atossa in support of our important partnership with the iSPY Network and QLHC. The innovative idea of combining (Z)-endoxifen and Lilly's FDA approved abemaciclib in the neoadjuvant setting can open the door to the development of gentler more patient-friendly treatment options for women with invasive breast tumors. By combining these therapies, we hope to achieve improved outcomes compared to available therapies, not only in terms of safety and efficacy, but also with respect to patients’ quality of life outcome measures. https://lnkd.in/gxRSU7eB

Aligned with the paper conclusion: The announcement by the FDA of the safety signal that the CAR T-cell product can itself become a cancer is a noteworthy step in the history of this product. This ability appears to be a class effect, affecting all products and approvals. Although rare, the malignant transformation of a cellular therapy is a concerning safety signal, and diligent efforts should be made to monitor it, ascertain the true incidence, and research efforts to avoid the risk. Many lives have been saved by CAR T-cell therapy and the product likely retains a net benefit in most approved indications.

Transcenta announces that it is going to present three posters highlighting study results from ongoing trials related to Osemitamab (TST001) and TST003 at AACR Annual Meeting 2024, including the safety, tolerability and pharmacokinetics profile of Osemitamab (TST001) administered as monotherapy or in combination with nivolumab or standard of care in patients with locally advanced or metastatic solid tumors (TranStar101: a Phase I/IIa clinical trial); prevalence of Claudin18.2 expression in gastric/gastroesophageal junction adenocarcinoma by Transcenta proprietary CLDN18.2 assay from US and Chinese patients from Transtar101 and Transtar102 clinical trials, as well as a first-in-human, open-label, multi-center phase 1 study of TST003, a GREM 1 inhibitor, in subjects with locally advanced or metastatic solid tumors. Read full news: https://lnkd.in/g5nghizb

Advances in the Treatment of Resectable NSCLC: Key Insights From CheckMate 77T, NEOSTAR, and CA209-159 Trials: Clinical research presented at ESMO 2024 highlights the significant survival benefits of perioperative and neoadjuvant immunotherapy with nivolumab and nivolumab plus ipilimumab, while emphasizing the role of biomarkers such as ctDNA and KRAS mutations in guiding treatment decisions. #finance #pharmacy #lifesciences

We are excited to announce initial Phase I data of JBI-802 a CoREST inhibitor, which shows therapeutic potential in immunotherapy resistant NSCLC patients with poor prognosis based on their genetic and metastatic pattern. In addition, the on-target dose/exposure-proportional decrease in platelet constitute a proof-of-principle that JBI-802 can be an active compound in hematological malignancies like Essential Thrombocythemia (ET) and other MPN/ MDS characterized by thrombocytosis. A follow up Phase I/II study in MPN/ET and MPN/MDS with thrombocytosis is being planned in first quarter of this year to investigate JBI-802 as potential novel treatment option. Read More: https://lnkd.in/gURiXNPq #nsclc #lungcancer #thrombocythemia #mpn #mds #lsd1 #corest

New Tumor Agnostic Drug: FDA Grants Approval to T-DXd in Advanced HER2-positive Solid Tumors https://lnkd.in/duMDnc5p Read also the article: “The Potential of Trastuzumab Deruxtecan as a Tissue Agnostic Drug": https://lnkd.in/eTwMwg27 #medicine #pharmaceuticals #oncology #percisionmedicine

At #HOPA2024, speaker Sandra Cuellar, PharmD, BCOP, FHOPA, FASHP, explained that precision medicine revolutionized NSCLC treatment, targeting specific mutations like KRAS G12C with therapies such as adagrasib (Krazati; Mirati Therapeutics) to improve patient outcomes. Learn more at rb.gy/zdx9u0 #PrecisionMedicine

Solid tumors remain a holy grail of #celltherapy, with many companies trying to "crack the code". And there isn't just one code - it is a wonderful and complex mix of biological factors that make solid tumors such a challenging target. It is exciting to see a new approach emerge from Poseida Therapeutics, Inc. at #AACR: https://lnkd.in/gwHwuVbJ

#Bispecific #Ivonescimab #NSCLC #PD-1 #VEGF Akeso ---Ivonescimab Is the First Drug to Achieve Clinically Meaningful Benefit over Pembrolizumab in Randomized Phase III Clinical Trial in NSCLC --Monotherapy Ivonescimab Achieved Clinically Meaningful PFS Benefit in HARMONi-2 Trial Conducted by Akeso --PFS Improvement Was Observed Broadly in Patients Across Subgroups, including PD-L1 Low and PD-L1 High Expressing Tumors, Squamous and Non-Squamous Histologies --- Ivonescimab is a bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule https://lnkd.in/grurkhXF